Modulations of Fetal-hemoglobin (HbF) and possibly hemoglobin-A2 (HbA2) are of interest given their potential roles in ameliorating beta thalassemia (beta thal) and sickle cell anemia phenotypes (1–4). This evidence concerns the gene HBA2 and Beta-thalassemia.